FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2079-2080 May 11, 2006 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Lenalidomide (Revlimid) is an analogue of thalidomide that has clinical activity in a variety of hematologic conditions.¹ It has recently been approved by the Food and Drug Administration for certain myelodysplastic syndromes associated with a chromosome 5q deletion. We report on the risk of thrombosis when lenalidomide is used with other agents that have known thrombogenic potential, including erythropoietin, and the need to consider antithrombotic prophylaxis when such combinations are administered.

This report is based on the preliminary evaluation of results of two recently completed placebo-controlled studies,² identical in design, involving patients with relapsed or refractory multiple . . . [Full Text of this Article]

This article has been cited by other articles:

• Kumar, S. K., Mikhael, J. R., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonseca, R., Gertz, M. A., Greipp, P. R., Hayman, S. R., Kyle, R. A., Lacy, M. Q., Lust, J. A., Reeder, C. B., Roy, V., Russell, S. J., Short, K. E. D., Stewart, A. K., Witzig, T. E., Zeldenrust, S. R., Dalton, R. J., Rajkumar, S. V., Bergsagel, P. L. (2009). Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines. Mayo Clin Proc. 84: 1095-1110 [Abstract] [Full Text]  
• Khorana, A. A., Connolly, G. C. (2009). Assessing Risk of Venous Thromboembolism in the Patient With Cancer. JCO 27: 4839-4847 [Abstract] [Full Text]  
• Richardson, P. G., Xie, W., Mitsiades, C., Chanan-Khan, A. A., Lonial, S., Hassoun, H., Avigan, D. E., Oaklander, A. L., Kuter, D. J., Wen, P. Y., Kesari, S., Briemberg, H. R., Schlossman, R. L., Munshi, N. C., Heffner, L. T., Doss, D., Esseltine, D.-L., Weller, E., Anderson, K. C., Amato, A. A. (2009). Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. JCO 27: 3518-3525 [Abstract] [Full Text]  
• Mitsiades, C. S., Rouleau, C., Echart, C., Menon, K., Teicher, B., Distaso, M., Palumbo, A., Boccadoro, M., Anderson, K. C., Iacobelli, M., Richardson, P. G. (2009). Preclinical Studies in Support of Defibrotide for the Treatment of Multiple Myeloma and Other Neoplasias. Clin. Cancer Res. 15: 1210-1221 [Abstract] [Full Text]  
• Johnson, D. C., Corthals, S., Ramos, C., Hoering, A., Cocks, K., Dickens, N. J., Haessler, J., Goldschmidt, H., Child, J. A., Bell, S. E., Jackson, G., Baris, D., Rajkumar, S. V., Davies, F. E., Durie, B. G. M., Crowley, J., Sonneveld, P., Van Ness, B., Morgan, G. J. (2008). Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 112: 4924-4934 [Abstract] [Full Text]  
• Kristinsson, S. Y., Fears, T. R., Gridley, G., Turesson, I., Mellqvist, U.-H., Bjorkholm, M., Landgren, O. (2008). Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma. Blood 112: 3582-3586 [Abstract] [Full Text]  
• Hazarika, M., Rock, E., Williams, G., Dagher, R., Sridhara, R., Booth, B., Farrell, A., Justice, R., Pazdur, R. (2008). Lenalidomide in Combination with Dexamethasone for the Treatment of Multiple Myeloma After One Prior Therapy. The Oncologist 13: 1120-1127 [Abstract] [Full Text]  
• Mitsiades, C. S., Ocio, E. M., Pandiella, A., Maiso, P., Gajate, C., Garayoa, M., Vilanova, D., Montero, J. C., Mitsiades, N., McMullan, C. J., Munshi, N. C., Hideshima, T., Chauhan, D., Aviles, P., Otero, G., Faircloth, G., Mateos, M. V., Richardson, P. G., Mollinedo, F., San-Miguel, J. F., Anderson, K. C. (2008). Aplidin, a Marine Organism-Derived Compound with Potent Antimyeloma Activity In vitro and In vivo. Cancer Res. 68: 5216-5225 [Abstract] [Full Text]  
• Rajkumar, S. V., Rosinol, L., Hussein, M., Catalano, J., Jedrzejczak, W., Lucy, L., Olesnyckyj, M., Yu, Z., Knight, R., Zeldis, J. B., Blade, J. (2008). Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma. JCO 26: 2171-2177 [Abstract] [Full Text]  
• Brown, E. N., Herrington, J. D. (2008). Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment. Journal of Pharmacy Practice 21: 126-137 [Abstract]  
• Chanan-Khan, A. A., Cheson, B. D. (2008). Lenalidomide for the Treatment of B-Cell Malignancies. JCO 26: 1544-1552 [Abstract] [Full Text]  
• Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N. M., Levine, M. N., Liebman, H., Mendelson, D., Raskob, G., Somerfield, M. R., Thodiyil, P., Trent, D., Francis, C. W. (2007). American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. JCO 25: 5490-5505 [Abstract] [Full Text]  
• Jadu, F., Lee, L., Pharoah, M., Reece, D., Wang, L. (2007). A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients. Ann Oncol 18: 2015-2019 [Abstract] [Full Text]  
• Khorana, A. A. (2007). The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: Strategies for Improving VTE Prophylaxis in Hospitalized Cancer Patients. The Oncologist 12: 1361-1370 [Abstract] [Full Text]  
• Palumbo, A., Falco, P., Corradini, P., Falcone, A., Di Raimondo, F., Giuliani, N., Crippa, C., Ciccone, G., Omede, P., Ambrosini, M. T., Gay, F., Bringhen, S., Musto, P., Foa, R., Knight, R., Zeldis, J. B., Boccadoro, M., Petrucci, M. T. (2007). Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA Italian Multiple Myeloma Network. JCO 25: 4459-4465 [Abstract] [Full Text]  
• Lacy, M. Q., Gertz, M. A., Dispenzieri, A., Hayman, S. R., Geyer, S., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., Lust, J. A., Russell, S. J., Kyle, R. A., Witzig, T. E., Bergsagel, P. L., Stewart, A. K., Rajkumar, S. V. (2007). Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Mayo Clin Proc. 82: 1179-1184 [Abstract] [Full Text]  
• Katzel, J. A., Hari, P., Vesole, D. H. (2007). Multiple Myeloma: Charging Toward a Bright Future. CA Cancer J Clin 57: 301-318 [Abstract] [Full Text]  
• Richardson, P. G., Mitsiades, C., Schlossman, R., Munshi, N., Anderson, K. (2007). New Drugs for Myeloma. The Oncologist 12: 664-689 [Abstract] [Full Text]  
• Fonseca, R., Stewart, A. K. (2007). Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach. Molecular Cancer Therapeutics 6: 802-810 [Abstract] [Full Text]  
• Dispenzieri, A., Rajkumar, S. V., Gertz, M. A., Lacy, M. Q., Kyle, R. A., Greipp, P. R., Witzig, T. E., Lust, J. A., Russell, S. J., Hayman, S. R., Kumar, S., Zeldenrust, S. R., Fonseca, R., Bergsagel, P. L., Reeder, C. B., Stewart, A. K., Roy, V., Dalton, R. J. (2007). Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement. Mayo Clin Proc. 82: 323-341 [Abstract] [Full Text]  
• Sanchorawala, V., Wright, D. G., Rosenzweig, M., Finn, K. T., Fennessey, S., Zeldis, J. B., Skinner, M., Seldin, D. C. (2007). Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 109: 492-496 [Abstract] [Full Text]  
• Hirsh, J. (2007). Risk of Thrombosis With Lenalidomide and Its Prevention With Aspirin. Chest 131: 275-277 [Abstract] [Full Text]  
• Eby, C. S. (2007). Bleeding and Thrombosis Risks in Plasma Cell Dyscrasias. ASH Education Book 2007: 158-164 [Abstract] [Full Text]  
• Richardson, P., Mitsiades, C., Schlossman, R., Ghobrial, I., Hideshima, T., Chauhan, D., Munshi, N., Anderson, K. (2007). The Treatment of Relapsed and Refractory Multiple Myeloma. ASH Education Book 2007: 317-323 [Abstract] [Full Text]  
• Bennett, C. L., Angelotta, C., Yarnold, P. R., Evens, A. M., Zonder, J. A., Raisch, D. W., Richardson, P. (2006). Thalidomide- and Lenalidomide-Associated Thromboembolism Among Patients With Cancer. JAMA 296: 2558-2560 [Full Text]  
• Zonder, J. A., Barlogie, B., Durie, B. G. M., McCoy, J., Crowley, J., Hussein, M. A., Rajkumar, S. V., Gertz, M. A. (2006). Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.. Blood 108: 403-404 [Full Text]  
• Fenaux, P., Kelaidi, C. (2006). Treatment of the 5q- Syndrome. ASH Education Book 2006: 192-198 [Abstract] [Full Text]  
• Zonder, J. A. (2006). Thrombotic Complications of Myeloma Therapy. ASH Education Book 2006: 348-355 [Abstract] [Full Text]